<DOC>
	<DOCNO>NCT01242098</DOCNO>
	<brief_summary>The purpose study evaluate whether beclomethasone dipropionate / formoterol ( BDP/FOR ; Fostair® 100/6 ) least equivalent term exacerbation prevention fluticasone dipropionate / salmeterol ( FP/SAL ; Seretide® 125 ) match asthma patient switch BDP/FOR follow treatment FP/SAL normal clinical practice compare patient switch .</brief_summary>
	<brief_title>Real-world Effectiveness Combination Therapies Primary Care Asthma Management</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Aged : 1860 year : 6180 year neversmokers Evidence asthma : diagnostic code asthma , ≥2 prescription asthma different point time prior year Baseline FP/SAL therapy : ≥2 prescription ICS/LABA therapy FP/SAL ( Seretide® 125 ) . Any chronic respiratory disease asthma Are receive maintenance oral steroid therapy baseline period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Primary care management</keyword>
	<keyword>Switch</keyword>
	<keyword>ICS/LABA</keyword>
	<keyword>Fostair</keyword>
	<keyword>Seretide</keyword>
</DOC>